CLSD stock forecast
Our latest prediction for Clearside Biomedical, Inc.'s stock price was made on the Nov. 12, 2019 when the stock price was at 1.11$.
In the short term (2weeks), CLSD's stock price should outperform the market by 4.89%. During that period the price should oscillate between -9.57% and +20.20%.
In the medium term (3months), CLSD's stock price should outperform the market by 11.68%. During that period the price should oscillate between -21.17% and +58.06%.Get email alerts
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.42$ per share.
The book value per share is 2.08$
Three months stock forecastNov. 12, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|